Mercer Global Advisors
AKBA icon

Mercer Global Advisors’s Akebia Therapeutics AKBA Stock Holding History

Mercer Global Advisors’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$127K Buy
111,756
+100,064
+856% +$119K ﹤0.01% 3373
2026
Q1 		$16.3K Buy
+11,692
New +$16.1K ﹤0.01% 3190
2024
Q4 		– Sell
-38,721
Closed -$49.6K – 2120
2024
Q3 		$49.6K Buy
38,721
+7,500
+24% +$10K ﹤0.01% 1916
2024
Q2 		$31.8K Buy
31,221
+9,037
+41% +$11.2K ﹤0.01% 1931
2024
Q1 		$41K Buy
22,184
+2,498
+13% +$3.99K ﹤0.01% 1899
2023
Q4 		$24K Sell
19,686
-274
-1% -$279 ﹤0.01% 1985
2023
Q3 		$23K Hold
19,960
– – ﹤0.01% 1921
2023
Q2 		$18K Buy
+19,960
New +$19.3K ﹤0.01% 1897

Other funds holding AKBA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Mercer Global Advisors's AKBA Position: Q2 2026 in Review

Mercer Global Advisors increased its Akebia Therapeutics (AKBA) stake by 856% in Q2 2026, buying an estimated $119K and bringing the position to 111,756 shares worth $127K. The position accounts for ﹤0.01% of the portfolio, ranked #3373.

Mercer Global Advisors first reported a position in AKBA in Q2 2023 and has held it in 8 quarters since. 171 funds tracked by Wall St. Rank hold AKBA as of Q2 2026.

  • Mercer Global Advisors held 111,756 shares of Akebia Therapeutics worth $127K as of Q2 2026.
  • Mercer Global Advisors bought 100,064 Akebia Therapeutics shares in Q2 2026, an estimated $119K.
  • Akebia Therapeutics made up ﹤0.01% of Mercer Global Advisors's portfolio in Q2 2026, its #3373 holding.
  • Mercer Global Advisors first reported a position in Akebia Therapeutics in Q2 2023 and has held it in 8 quarters since.
  • 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2026.

Based on Mercer Global Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.